Supernus Pharmaceuticals ROE 2011-2024 | SUPN

Current and historical return on equity (ROE) values for Supernus Pharmaceuticals (SUPN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Supernus Pharmaceuticals ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-09-30 $0.06B $1.01B 6.19%
2024-06-30 $0.01B $0.96B 0.54%
2024-03-31 $-0.02B $0.93B -1.74%
2023-12-31 $0.00B $0.92B 0.11%
2023-09-30 $0.03B $0.91B 2.75%
2023-06-30 $0.04B $0.92B 4.82%
2023-03-31 $0.05B $0.91B 5.96%
2022-12-31 $0.06B $0.89B 7.16%
2022-09-30 $0.04B $0.85B 4.55%
2022-06-30 $0.06B $0.84B 7.04%
2022-03-31 $0.07B $0.83B 9.14%
2021-12-31 $0.05B $0.82B 6.82%
2021-09-30 $0.08B $0.81B 10.73%
2021-06-30 $0.10B $0.79B 13.49%
2021-03-31 $0.11B $0.75B 15.59%
2020-12-31 $0.13B $0.75B 18.73%
2020-09-30 $0.13B $0.71B 20.13%
2020-06-30 $0.12B $0.67B 19.58%
2020-03-31 $0.12B $0.61B 20.45%
2019-12-31 $0.11B $0.60B 20.97%
2019-09-30 $0.11B $0.56B 21.06%
2019-06-30 $0.11B $0.52B 22.36%
2019-03-31 $0.10B $0.48B 23.61%
2018-12-31 $0.11B $0.45B 27.46%
2018-09-30 $0.10B $0.42B 27.67%
2018-06-30 $0.09B $0.39B 27.60%
2018-03-31 $0.07B $0.35B 26.55%
2017-12-31 $0.06B $0.27B 23.90%
2017-09-30 $0.06B $0.25B 25.94%
2017-06-30 $0.10B $0.23B 51.50%
2017-03-31 $0.10B $0.21B 56.39%
2016-12-31 $0.09B $0.19B 63.64%
2016-09-30 $0.08B $0.17B 71.79%
2016-06-30 $0.03B $0.11B 27.81%
2016-03-31 $0.02B $0.10B 21.43%
2015-12-31 $0.01B $0.09B 18.48%
2015-09-30 $0.01B $0.08B 17.19%
2015-06-30 $0.01B $0.07B 9.39%
2015-03-31 $0.01B $0.06B 13.79%
2014-12-31 $-0.01B $0.04B -31.65%
2014-09-30 $-0.04B $0.04B -112.98%
2014-06-30 $-0.06B $0.03B -220.56%
2014-03-31 $-0.09B $0.03B -323.64%
2013-12-31 $-0.09B $0.03B -298.36%
2013-09-30 $-0.08B $0.01B -225.85%
2013-06-30 $-0.07B $0.04B -180.00%
2013-03-31 $-0.06B $0.04B -135.80%
2012-12-31 $-0.05B $0.06B -155.37%
2012-09-30 $0.05B $0.03B 272.22%
2012-06-30 $0.05B $0.04B 434.04%
2012-03-31 $0.05B $0.00B 2355.56%
2011-12-31 $0.05B $0.01B 2266.67%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00